United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.98, $0.82 better than the analyst estimate of $3.16. Revenue for the quarter came in at $444.5 million versus the consensus estimate of $368.58 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.